Search details
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38043558
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38621400
3.
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Prostate
; 84(8): 747-755, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38544345
4.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol
; 185: 128-137, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38412736
5.
Timing of prognostic discussions in people with advanced cancer: a systematic review.
Support Care Cancer
; 32(2): 127, 2024 Jan 23.
Article
in English
| MEDLINE | ID: mdl-38261070
6.
Patients' perception of the benefits of palliative systemic therapy for advanced cancer.
Intern Med J
; 54(5): 735-741, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38205872
7.
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(5): 468-482, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37080223
8.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36990608
9.
Prognostic value of patient reported outcomes in advanced gastro-oesophageal cancer: a systematic review.
Intern Med J
; 53(11): 1946-1955, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37605848
10.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36261050
11.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Article
in English
| MEDLINE | ID: mdl-33581798
12.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Article
in English
| MEDLINE | ID: mdl-31157964
13.
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
BMC Med
; 20(1): 112, 2022 03 25.
Article
in English
| MEDLINE | ID: mdl-35331214
14.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35718565
15.
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
BJU Int
; 129(5): 591-600, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34273231
16.
Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals.
Support Care Cancer
; 30(9): 7763-7772, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35701634
17.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Int J Gynecol Cancer
; 32(6): 761-768, 2022 06 06.
Article
in English
| MEDLINE | ID: mdl-35086926
18.
Palliative care facilitates the preparedness of caregivers for thoracic cancer patients.
Eur J Cancer Care (Engl)
; 31(6): e13716, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36169179
19.
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research.
Lancet Oncol
; 22(8): e369-e376, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34216541
20.
Physician-patient communication of costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines.
BMC Cancer
; 21(1): 1036, 2021 Sep 16.
Article
in English
| MEDLINE | ID: mdl-34530765